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Abstract
The vision for precision medicine is to use individual patient characteristics
to inform a personalized treatment plan that leads to the best possible health-
care for each patient. Mobile technologies have an important role to play in this
vision as they offer a means to monitor a patient’s health status in real-time
and subsequently to deliver interventions if, when, and in the dose that they are
needed. Dynamic treatment regimes formalize individualized treatment plans as
sequences of decision rules, one per stage of clinical intervention, that map cur-
rent patient information to a recommended treatment. However, most existing
methods for estimating optimal dynamic treatment regimes are designed for a
small number of fixed decision points occurring on a coarse time-scale. We pro-
pose a new reinforcement learning method for estimating an optimal treatment
regime that is applicable to data collected using mobile technologies in an out-
patient setting. The proposed method accommodates an indefinite time horizon
and minute-by-minute decision making that are common in mobile health appli-
cations. We show that the proposed estimators are consistent and asymptotically
normal under mild conditions. The proposed methods are applied to estimate an
optimal dynamic treatment regime for controlling blood glucose levels in patients
with type 1 diabetes.
Keywords: Markov decision processes, Precision medicine, Reinforcement learning,
Type 1 diabetes
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1 Introduction
The use of mobile devices in clinical care, called mobile health (mHealth), provides an
effective and scalable platform to assist patients in managing their illness (Free et al.,
2013; Steinhubl et al., 2013). Advantages of mHealth interventions include real-time
communication between a patient and their health-care provider as well as systems for
delivering training, teaching, and social support (Kumar et al., 2013). Mobile tech-
nologies can also be used to collect rich longitudinal data to estimate optimal dynamic
treatment regimes and to deliver treatment that is deeply tailored to each individual
patient. We propose a new estimator of an optimal treatment regime that is suitable
for use with with longitudinal data collected in mHealth applications.
A dynamic treatment regime provides a framework to administer individualized
treatment over time through a series of decision rules. Dynamic treatment regimes have
been well-studied in the statistical and biomedical literature (Murphy, 2003; Robins,
2004; Moodie et al., 2007; Kosorok and Moodie, 2015; Chakraborty and Moodie, 2013)
and furthermore, statistical considerations in mHealth have been studied by, for exam-
ple, Liao et al. (2015) and Klasnja et al. (2015). Although mobile technology has been
successfully utilized in clinical areas such as diabetes (Quinn et al., 2011; Maahs et al.,
2012), smoking cessation (Ali et al., 2012), and obesity (Bexelius et al., 2010), mHealth
poses some unique challenges that preclude direct application of existing methodologies
for dynamic treatment regimes. For example, mHealth applications typically involve a
large number of time points per individual and no definite time horizon; the momen-
tary signal may be weak and may not directly measure the outcome of interest; and
estimation of optimal treatment strategies must be done online as data accumulate.
This work is motivated in part by our involvement in a study of mHealth as a
management tool for type 1 diabetes. Type 1 diabetes is an autoimmune disease
wherein the pancreas produces insufficient levels of insulin, a hormone needed to regu-
late blood glucose concentration. Patients with type 1 diabetes are continually engaged
in management activities including monitoring glucose levels, timing and dosing in-
sulin injections, and regulating diet and physical activity. Increased glucose monitoring
and attention to self-management facilitate more frequent treatment adjustments and
have been shown to improve patient outcomes (Levine et al., 2001; Haller et al., 2004;
Ziegler et al., 2011). Thus, patient outcomes have the potential to be improved by di-
abetes management tools which are deeply tailored to the continually evolving health
status of each patient. Mobile technologies can be used to collect data on physical ac-
tivity, glucose, and insulin at a fine granularity in an outpatient setting (Maahs et al.,
2012). There is great potential for using these data to create comprehensive and acces-
sible mHealth interventions for clinical use. We envision application of this work for use
before the artificial pancreas (Weinzimer et al., 2008; Kowalski, 2015; Bergenstal et al.,
2016) becomes widely available.
The sequential decision making process can be modeled as a Markov decision pro-
cess (Puterman, 2014) and the optimal treatment regime can be estimated using re-
inforcement learning algorithms such as Q-learning (Murphy, 2005; Zhao et al., 2009;
Tang and Kosorok, 2012; Schulte et al., 2014). Ertefaie (2014) proposed a variant of
greedy gradient Q-learning (GGQ) to estimate optimal dynamic treatment regimes in
infinite horizon settings (see also Maei et al., 2010). In GGQ, the form of the estimated
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Q-function dictates the form of the estimated optimal treatment regime. Thus, one
must choose between a parsimonious model for the Q-function at the risk of model
misspecification or a complex Q-function that yields unintelligible treatment regimes.
Furthermore, GGQ requires modeling a non-smooth function of the data, which cre-
ates complications (Laber et al., 2014; Linn et al., 2017). We propose an alternative
estimation method for infinite horizon dynamic treatment regimes that is suited to
mHealth applications. Our approach, which we call V-learning, involves estimating the
optimal policy among a prespecified class of policies (Zhang et al., 2012, 2013). It re-
quires minimal assumptions about the data-generating process and permits estimating
a randomized decision rule that can be implemented online as data accumulate.
In Section 2, we describe the setup and present our method for offline estimation
using data from a micro-randomized trial or observational study. In Section 3, we extend
our method for application to online estimation with accumulating data. Theoretical
results, including consistency and asymptotic normality of the proposed estimators, are
presented in Section 4. We compare the proposed method to GGQ using simulated data
in Section 5. A case study using data from patients with type 1 diabetes is presented
in Section 6 and we conclude with a discussion in Section 7. Proofs of technical results
are in the Appendix.
2 Offline estimation from observational data
We assume that the available data are
{(
S
1
i , A
1
i ,S
2
i , . . . ,S
Ti
i , A
Ti
i ,S
Ti+1
i
)}n
i=1
, which
comprise n independent, identically distributed trajectories
(
S
1, A1,S2, . . . ,ST , AT ,ST+1
)
,
where: St ∈ Rp denotes a summary of patient information collected up to and including
time t; At ∈ A denotes the treatment assigned at time t; and T ∈ Z+ denotes the (pos-
sibly random) patient follow-up time. In the motivating example of type 1 diabetes,
S
t could contain a patient’s blood glucose, dietary intake, and physical activity in the
hour leading up to time t and At could denote an indicator that an insulin injection
is taken at time t. We assume that the data-generating model is a time-homogeneous
Markov process so that St+1 ⊥ (At−1,St−1, . . . , A1,S1)∣∣(At,St) and the conditional
density p(st+1|at, st) is the same for all t ≥ 1. Let Lt ∈ {0, 1} denote an indicator
that the patient is still in follow-up at time t, i.e., Lt = 1 if the patient is being fol-
lowed at time t and zero otherwise. We assume that Lt is contained in St so that
P (Lt+1 = 1|At,St, . . . , A1,S1) = P (Lt+1 = 1|At,St) and Lt = 0 implies Lt+1 = 0 with
probability one. Furthermore, we assume a known utility function u : Rp×A×Rp → R
so that U t = u(St+1, At,St) measures the ‘goodness’ of choosing treatment At in state
S
t and subsequently transitioning to state St+1. In our motivating example, the utility
at time t could be a measure of how far the patient’s average blood glucose concentration
deviates from the optimal range over the hour preceding and following time t. The goal
is to select treatments to maximize expected cumulative utility; treatment selection is
formalized using a treatment regime (Schulte et al., 2014; Kosorok and Moodie, 2015)
and the utility associated with any regime is defined using potential outcomes (Rubin,
1978).
Let B(A) denote the space of probability distributions over A. A treatment regime
in this context is a function π : domSt → B(A) so that, under π, a decision maker
presented with state St = st at time t will select action at ∈ A with probability
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π(at; st). Define at = (a1, . . . , at) ∈ At, and a∞ = (a1, a2, . . .) ∈ A∞. The set of
potential outcomes is
W
∗ =
{
S
1,S∗2(a1), . . . ,S∗T
∗(a∞)(aT
∗(a∞)−1) :
T ∗(a∞) = inf
{
t ≥ 1 : L∗t(at−1) = 0} , a∞ ∈ A∞},
where S∗t(at−1) is the potential state and L∗t(at−1) is the potential follow-up sta-
tus at time t under treatment sequence at−1. Thus, the potential utility at time t
is U∗t(at) = u
{
S
∗(t+1)(at), at,S∗t(at−1)
}
. For any π, define {ξtpi(·)}t≥1 to be a se-
quence of independent, A-valued stochastic processes indexed by domSt such that
P {ξtpi(st) = at} = π(at; st). The potential follow-up time under π is
T ∗(π) =
∑
t≥1
∑
at∈At
t1
{
supat+1T
∗(at, at+1) = t
} t∏
v=1
1
[
ξvpi
{
S
∗v(av−1)
}
= av
]
,
where at+1 = (at+1, at+2, . . .). The potential utility under π at time t is
U∗t(π) =
{ ∑
at∈At U
∗t (at)
∏t
v=1 1 [ξ
v
pi {S∗v(av−1)} = av] , if T ∗(π) ≥ t
0, otherwise,
where S∗1(a0) = S1. Thus, utility is set to zero after a patient is lost to follow-up.
However, in certain situations, utility may be constructed so as to take a negative value
at the time point when the patient is lost to follow-up, e.g., if the patient discontinues
treatment because of a negative effect associated with the intervention. Define the state-
value function V (π, st) = E
{∑
k≥0 γ
kU∗(t+k)(π)
∣∣St = st} (Sutton and Barto, 1998),
where γ ∈ (0, 1) is a fixed constant that captures the trade-off between short- and
long-term outcomes. For any distribution R on domS1, define the value function with
respect to reference distribution R as VR(π) =
∫
V (π, s)dR(s); throughout, we assume
that this reference distribution is fixed. The reference distribution can be thought of as
a distribution of initial states and we estimate it from the data in the implementation
in Sections 5 and 6. For a prespecified class of regimes, Π, the optimal regime, πoptR ∈ Π,
satisfies VR(π
opt
R ) ≥ VR(π) for all π ∈ Π.
To construct an estimator of πoptR , we make a series of assumptions that connect the
potential outcomes in W ∗ with the data-generating model.
Assumption 1. Strong ignorability, At ⊥ W ∗∣∣St for all t.
Assumption 2. Consistency, St = S∗t(A
t−1
) for all t and T = T ∗(A
∞
).
Assumption 3. Positivity, there exists c0 > 0 so that P (A
t = at|St = st) ≥ c0 for all
at ∈ A, st ∈ domSt, and all t.
In addition, we implicitly assume that there is no interference among the experi-
mental units. These assumptions are common in the context of estimating dynamic
treatment regimes (Robins, 2004; Schulte et al., 2014). Assumptions 1 and 3 hold by
construction in a micro-randomized trial (Klasnja et al., 2015; Liao et al., 2015).
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Let µt(at; st) = P (At = at|St = st) for each t ≥ 1. In a micro-randomized trial,
µt(at; st) is a known randomization probability; in an observational study, it must be
estimated from the data. The following lemma characterizes VR(π) for any regime, π,
in terms of the data-generating model (see also Lemma 4.1 of Murphy et al., 2001). A
proof is provided in the appendix.
Lemma 2.1. Let π denote an arbitrary regime and γ ∈ (0, 1) a discount factor. Then,
under assumptions 1-3 and provided interchange of the sum and integration is justified,
the state-value function of π at st is
V (π, st) =
∑
k≥0
E
[
γkU t+k
{
k∏
v=0
π(Av+t;Sv+t)
µv+t(Av+t;Sv+t)
}∣∣∣∣St = st
]
. (1)
The preceding result will form the basis for an estimating equation for VR(π). Write
the right hand side of (1) as
V (π,St) = E
{
π(At;St)
µt(At;St)
(
U t + γ
∑
k≥0
E
[
γkU t+k+1
{
k∏
v=0
π(Av+t+1;Sv+t+1)
µv+t+1(Av+t+1;Sv+t+1)
}∣∣∣∣St+1
]) ∣∣∣∣St
}
= E
[
π(At;St)
µt(At;St)
{
U t + γV (π,St+1)
} ∣∣∣∣St] ,
from which it follows that
0 = E
[
π(At;St)
µt(At;St)
{
U t + γV (π,St+1)− V (π,St)} ∣∣∣∣St] .
Subsequently, for any function ψ defined on domSt, the state-value function satisfies
0 = E
[
π(At;St)
µt(At;St)
{
U t + γV (π,St+1)− V (π,St)}ψ(St)] , (2)
which is an importance-weighted variant of the well-known Bellman optimality equation
(Sutton and Barto, 1998).
Let V (π, s; θpi) denote a model for V (π, s) indexed by θpi ∈ Θ ⊆ Rq. We assume
that the map θpi 7→ V (π, s; θpi) is differentiable everywhere for each fixed s and π. Let
∇θpiV (π, s; θpi) denote the gradient of V (π, s; θpi) and define
Λn(π, θ
pi) =
1
n
n∑
i=1
Ti∑
t=1
π(Ati;S
t
i)
µt(Ati;S
t
i)
{
U ti + γV (π,S
t+1
i ; θ
pi)− V (π,Sti; θpi)
}∇θpiV (π,Sti; θpi).
(3)
Given a positive definite matrix Ω ∈ Rq×q and penalty function P : Rq → R+, define
θ̂pin = argminθpi∈Θ {Λn(π, θpi)⊺ΩΛn(π, θpi) + λnP(θpi)}, where λn is a tuning parameter.
Subsequently, V
(
π, s; θ̂pin
)
is the estimated state-value function under π in state s.
Thus, given a reference distribution, R, the estimated value of a regime, π, is V̂n,R(π) =∫
V
(
π, s; θ̂pin
)
dR(s) and the estimated optimal regime is π̂n = argmaxpi∈Π V̂n,R(π).
The idea of V-learning is to use estimating equation (3) to estimate the value of any
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policy and maximize estimated value over a class of policies; we will discuss strategies
for this maximization in Section 5.
V-learning requires a parametric class of policies. Assuming that there are K
possible treatments, a1, . . . , aK , we can define a parametric class of policies as fol-
lows. Define π(aj ; s, β) = exp(s
⊺βj)/
{
1 +
∑K−1
k=1 exp(s
⊺βk)
}
for j = 1, . . . , K − 1,
and π(aK ; s) = 1/
{
1 +
∑K−1
k=1 exp(s
⊺βk)
}
. This defines a class of randomized policies
parametrized by β = (β⊺1 , . . . , β
⊺
K−1)
⊺, where βk is a vector of parameters for the k-th
treatment. Under a policy in this class defined by β, actions are selected stochasti-
cally according to the probabilities π(aj; s, β), j = 1, . . . , K. In the case of a binary
treatment, a policy in this class reduces to π(1; s, β) = exp(s⊺β)/ {1 + exp(s⊺β)} and
π(0; s, β) = 1/ {1 + exp(s⊺β)} for a p× 1 vector β. This class of policies is used in the
implementation in Sections 5 and 6.
V-learning also requires a class of models for the state value function indexed by a
parameter, θpi. We use a basis function approximation. Let Φ = (φ1, . . . , φq)
⊺ be a vector
of prespecified basis functions and let Φ(sti) = {φ1(sti), . . . , φq(sti)}⊺. Let V (π, sti; θpi) =
Φ(sti)
⊺θpi. Under this working model,
Λn(π, θ
pi) =
[
n−1
n∑
i=1
Ti∑
t=1
π(Ati;S
t
i)
µt(Ati;S
t
i)
{
γΦ(Sti)Φ(S
t+1
i )
⊺ − Φ(Sti)Φ(Sti)⊺
}]
θpi (4)
+n−1
n∑
i=1
Ti∑
t=1
{
π(Ati;S
t
i)
µt(Ati;S
t
i)
U tiΦ(S
t
i)
}
.
Computational efficiency is gained from the linearity of V (π, sti; θ
pi) in θpi; flexibility can
be achieved through the choice of Φ. We examine the performance of V-learning using
a variety of basis functions in Sections 5 and 6.
3 Online estimation from accumulating data
Suppose we have accumulating data
{(
S
1
i , A
1
i ,S
2
i , . . .
)}n
i=1
, where Sti and A
t
i represent
the state and action for patient i = 1, . . . , n at time t ≥ 1. At each time t, we estimate
an optimal policy in a class, Π, using data collected up to time t, take actions according
to the estimated optimal policy, and estimate a new policy using the resulting states.
Let π̂tn be the estimated policy at time t, i.e., π̂
t
n is estimated after observing state S
t+1
and before taking action At+1. If Π is a class of randomized policies, we can select an
action for a patient presenting with St+1 = st+1 according to π̂tn(·; st+1), i.e., we draw
At+1 according to the distribution P (At+1 = a) = π̂tn(a; s
t+1). If a class of deterministic
policies is of interest, we can inject some randomness into π̂tn to facilitate exploration.
One way to do this is an ǫ-greedy strategy (Sutton and Barto, 1998), which selects the
estimated optimal action with probability 1− ǫ and otherwise samples equally from all
other actions. Because an ǫ-greedy strategy can be used to introduce randomness into
a deterministic policy, we can assume a class of randomized policies.
At each time t ≥ 1, let θ̂pin,t = argminθpi∈Θ {Λn,t(π, θpi)⊺ΩΛn,t(π, θpi) + λnP(θpi)},
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where Ω, λn, and P are as defined in Section 2 and
Λn,t(π, θ
pi) =
1
n
n∑
i=1
t∑
v=1
π(Avi ;S
v
i )
π̂v−1n (A
v
i ;S
v
i )
{
Uvi + γV (π,S
v+1
i ; θ
pi)− V (π,Svi ; θpi)
}∇θpiV (π,Svi ; θpi)
(5)
with π̂0n some initial randomized policy. We note that estimating equation (5) is similar
to (3), except that π̂v−1n replaces µ
v as the data-generating policy. Given the estimator of
the value of π at time t, V̂n,R,t(π) =
∫
V
(
π, s; θ̂pin,t
)
dR(s), the estimated optimal policy
at time t is π̂tn = argmaxpi∈ΠV̂n,R,t(π). In practice, we may choose to update the policy
in batches rather than at every time point. An alternative way to encourage exploration
through the action space is to choose π̂tn = argmaxpi∈Π
{
V̂n,R,t(π) + α
tψ̂t(π)
}
for some
sequence αt ≥ 0, where ψ̂t(π) is a measure of uncertainty in V̂n,R,t(π). An example of
this is upper confidence bound sampling, or UCB (Lai and Robbins, 1985).
It some settings, when the data-generating process may vary across patients, it may
be desirable to allow each patient to follow an individualized policy that is estimated
using only that patient’s data. Suppose that n patients are followed for an initial
T1 time points after which the policy π̂
1
n is estimated. Then, suppose that patient i
follows π̂1n until time T2, when a policy π̂
2
i is estimated using only the states and actions
observed for patient i. This procedure is then carried out until time TK for some fixed
K with each patient following their own individual policy which is adapted to match the
individual over time. We may also choose to adapt the randomness of the policy at each
estimation. For example, we could select ǫ1 > ǫ2 > . . . > ǫK and, following estimation
k, have patient i follow policy π̂ki with probability 1− ǫk and policy π̂1n with probability
ǫk. In this way, patients become more likely to follow their own individualized policy
and less likely to follow the initial policy over time, reflecting increasing confidence in
the individualized policy as more data become available. The same class of policies and
model for the state value function can be used as in Section 2.
4 Theoretical results
In this section, we establish asymptotic properties of θ̂pin and π̂n for offline estimation.
Throughout, we assume assumptions 1-3 from Section 2.
Let θ̂pin = argminθpi∈Θ {Λn(π, θpi)⊺Λn(π, θpi) + λn(θpi)⊺θpi}. Thus, we use the squared
Euclidean norm of θ as the penalty function; we will assume that λn = oP (n
−1/2).
For simplicity, we let Ω be the identity matrix. Assume the working model for the
state value function introduced in Section 2, i.e., V (π, sti; θ
pi) = Φ(sti)
⊺θpi. For fixed
π, denote the true θpi by θpi0 , i.e., V (π, s) = Φ(s)
⊺θpi0 . Let ν =
∫
Φ(s)dR(s) so that
VR(π) = ν
⊺θpi0 . Define V̂n,R̂(π) = {EnΦ(S)}⊺ θ̂pin, where En denotes the empirical measure
of the observed data. Let Π = {πβ : β ∈ B} be a parametric class of policies and let
π̂n = πβ̂n where β̂n = argmaxβ∈B V̂n,R̂(πβ).
Our main results are summarized in Theorems 4.2 and 4.3 below. Because each
patient trajectory is a stationary Markov chain, we need to use asymptotic theory
based on stationary processes; consequently, some of the required technical conditions
are more difficult to verify than those for i.i.d. data. Define the bracketing integral
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for a class of functions, F , by J[] {δ,F , Lr(P )} =
∫ δ
0
√
logN[] {ǫ,F , Lr(P )}dǫ, where
the bracketing number for F , N[] {ǫ,F , Lr(P )}, is the number of Lr(P ) ǫ-brackets
needed such that each element of F is contained in at least one bracket (see Chap-
ter 2 of Kosorok, 2008). For any stationary sequence of possibly dependent ran-
dom variables, {X t}t≥1, let Mcb be the σ-field generated by Xb, . . . , Xc and define
ζ(k) = E
[
supm≥1
{|P (B|Mm1 )− P (B)| : B ∈M∞m+k}]. We say that the chain {X t}t≥1
is absolutely regular if ζ(k) → 0 as k → 0 (also called β-mixing in Chapter 11 of
Kosorok, 2008). We make the following assumptions.
Assumption 4. There exists a 2 < ρ <∞ such that
1. E|U t|3ρ <∞, E‖Φ(St)‖3ρ <∞, and E‖St‖3ρ <∞.
2. The sequence {(St, At)}t≥1 is absolutely regular with
∑∞
k=1 k
2/(ρ−2)ζ(k) <∞.
3. The bracketing integral of the class of policies, J[] {∞,Π, L3ρ(P )} <∞.
Assumption 5. There exists some c1 > 0 such that
inf
pi∈Π
c⊺E
[
π(At;St)
µt(At;St)
{
Φ(St)Φ(St)⊺ − γ2Φ(St+1)Φ(St+1)⊺}] c ≥ c1‖c‖2
for all c ∈ Rq.
Assumption 6. The map β 7→ VR(πβ) has a unique and well separated maximum over
β in the interior of B; let β0 denote the maximizer.
Assumption 7. The following condition holds: sup‖β1−β2‖≤δ E‖πβ1(A;S)−πβ2(A;S)‖ →
0 as δ ↓ 0.
Remark 4.1. Assumption 4 requires certain finite moments and that the dependence
between observations on the same patient vanishes as observations become further apart.
In Lemma 7.2 in the appendix, we verify part 3 of assumption 4 and assumption 7 for
the class of policies introduced in Section 2. However, note that the theory holds for
any class of policies satisfying the given assumptions, not just the class considered
here. Assumption 5 is needed to show the existence of a unique θpi0 uniformly over Π
and assumption 6 requires that the true optimal decision in each state is unique (see
assumption A.8 of Ertefaie, 2014). Assumption 7 requires smoothness on the class of
policies.
The main results of this section are stated below. Theorem 4.2 states that there
exists a unique solution to 0 = EΛn(π, θ
pi) uniformly over Π and that the estimator θ̂n
converges weakly to a mean zero Gaussian process in ℓ∞(Π).
Theorem 4.2. Under the given assumptions, the following hold.
1. For all π ∈ Π, there exists a θpi0 ∈ Rq such that EΛn(π, θpi) has a zero at θpi = θpi0 .
Moreover, suppi∈Π ‖θpi0‖ <∞ and sup‖β1−β2‖≤δ
∥∥θpiβ10 − θpiβ20 ∥∥→ 0 as δ ↓ 0.
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2. Let G(π) be a tight, mean zero Gaussian process indexed by Π with covariance
E {G(π1)G(π2)} = w1(π1)−1w0(π1, π2)w1(π2)−⊺ where
w0(π1, π2) = E
[
π1(A
t;St)π2(A
t;St)
µt(At;St)2
{
U t + γΦ(St+1)θpi10 − Φ(St)θpi10
}
{
U t + γΦ(St+1)θpi20 − Φ(St)θpi20
}
Φ(St)Φ(St)⊺
]
and
w1(π) = E
[
π(At;St)
µt(At;St)
Φ(St)
{
Φ(St)− γΦ(St+1)}⊺] .
Then,
√
n
(
θ̂pin − θpi0
)
 G(π) in ℓ∞(Π).
3. Let G(π) be as defined in part 2. Then,
√
n
{
V̂n,R̂(π)− VR(π)
}
 ν⊺G(π) in
ℓ∞(Π).
Theorem 4.3 below gives us that the estimated optimal policy converges in proba-
bility to the true optimal policy over Π and that the estimated value of the estimated
optimal policy converges to the true value of the estimated optimal policy.
Theorem 4.3. Under the given assumptions, the following hold.
1. Let β̂n = argmaxβ∈BV̂n,R̂(πβ) and β0 = argmaxβ∈BVR(πβ). Then,
∥∥∥β̂n − β0∥∥∥ P−→
0.
2. Let σ20 = ν
⊺w1(πβ0)
−1w0(πβ0 , πβ0)w1(πβ0)
−⊺ν. Then,
√
n
{
V̂n,R̂
(
πβ̂n
)
− VR
(
πβ̂n
)}
 
N(0, σ20).
3. A consistent estimator for σ20 is
σ̂2n =
{
EnΦ(S
t)
}
⊺
ŵ1
(
πβ̂n
)−1
ŵ0
(
πβ̂n, πβ̂n
)
ŵ1
(
πβ̂n
)−⊺ {
EnΦ(S
t)
}
,
where
ŵ0(π1, π2) = En
[
π1(A
t;St)π2(A
t;St)
µt(At;St)2
{
U t + γΦ(St+1)θ̂pi1n − Φ(St)θ̂pi1n
}
{
U t + γΦ(St+1)θ̂pi2n − Φ(St)θ̂pi2n
}
Φ(St)Φ(St)⊺
]
and
ŵ1(π) = En
[
π(At;St)
µt(At;St)
Φ(St)
{
Φ(St)− γΦ(St+1)}⊺] .
Proofs of the above results are in the Appendix along with a result on bracketing
entropy that is needed for the proof of Theorem 4.2 and a proof that the class of policies
introduced above satisfies the necessary bracketing integral assumption.
9
5 Simulation experiments
In this section, we examine the performance of V-learning on simulated data. Sec-
tion 5.2 contains results for offline estimation and Section 5.3 contains results for online
estimation. We begin by discussing an existing method for infinite horizon dynamic
treatment regimes in Section 5.1
5.1 Greedy gradient Q-learning
Ertefaie (2014) introduced greedy gradient Q-learning (GGQ) for estimating dynamic
treatment regimes in infinite horizon settings (see also Maei et al., 2010; Murphy et al.,
2016). Here we briefly discuss this method.
Define Qpi(st, at) = E
{∑
k≥0 γ
kU t+k(π)
∣∣∣St = st, At = at}. The Bellman optimality
equation (Sutton and Barto, 1998) is
Qopt(st, at) = E
{
U t + γmax
a∈A
Qopt(St+1, a)
∣∣∣St = st, At = at} . (6)
Let Q(s, a; ηopt) be a parametric model for Qopt(s, a) indexed by ηopt ∈ H ⊆ Rq.
In our implementation, we model Q(s, a; ηopt) as a linear function with interactions
between all state variables and treatment. The Bellman optimality equation motivates
the estimating equation
Dn
(
ηopt
)
=
1
n
n∑
i=1
Ti∑
t=1
{
U ti + γmax
a∈A
Q(St+1i , a; η
opt)−Q(Sti, Ati; ηopt)
}
∇ηoptQ(Sti, Ati; ηopt).
(7)
For a positive definite matrix, Ω, we estimate ηopt using η̂optn = argminη∈HDn(η)
⊺ΩDn(η).
The estimated optimal policy in state s selects action π̂n(s) = maxa∈AQ(s, a; η̂
opt
n ).
This optimization problem is non-convex and non-differentiable in ηopt. However, it
can be solved with a generalization of the greedy gradient Q-learning algorithm of
Maei et al. (2010), and hence is referred to as GGQ by Ertefaie (2014) and in the
following.
The performance of GGQ has been demonstrated in the context of chronic diseases
with large sample sizes and a moderate number of time points. However, in mHealth
applications, it is common to have small sample sizes and a large number of time
points, with decisions occurring at a fine granularity. In GGQ, the estimated policy
depends directly on η̂optn and, therefore, depends on modeling the transition probabilities
of the data-generating process. Furthermore, estimating equation (7) contains a non-
smooth max operator, which makes estimation difficult without large amounts of data
(Laber et al., 2014; Linn et al., 2017). V-learning only requires modeling the policy
and the value function rather than the data-generating process and directly maximizes
estimated value over a class of policies, thereby avoiding the non-smooth max operator
in the estimating equation (compare equations (3) and (7)); these attributes may prove
advantageous in mHealth settings.
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5.2 Offline simulations
Our implementation of V-learning follows the setup in Section 2. Maximizing V̂n,R(π)
is done using a combination of simulated annealing and the BFGS algorithm as im-
plemented in the optim function in R software (R Core Team, 2016). We note that
V̂n,R(π) is differentiable in π, thereby avoiding some of the computational complexity of
GGQ. However, the objective is not necessarily convex. In order to avoid local maxima,
simulated annealing with 1000 function evaluations is used to find a neighborhood of
the maximum; this solution is then used as the starting value for the BFGS algorithm.
We use the class of policies introduced in Section 2. Although we maximize the value
over a class of randomized policies, the true optimal policy is deterministic. To prevent
the coefficients of β̂n from diverging to infinity, we add an L2 penalty when maximizing
over β. To prevent overfitting, we use an L2 penalty when computing θ̂pin , i.e., P(θpi) =
(θpi)⊺θpi. Tuning parameters can be used to control the amount of randomness in the
estimated policy. For example, increasing the penalty when computing β̂n is one way
to encourage exploration through the action space because β = 0 defines a policy where
each action is selected with equal probability.
We consider three different models for the state-value function: (i) linear; (ii) second
degree polynomial; and (iii) Gaussian radial basis functions (RBF). The Gaussian RBF
is φ(x; κ, τ 2) = exp {−(x− κ)2/2τ 2}. We use τ = 0.25 and κ = 0, 0.25, 0.5, 0.75, 1 to
create a basis of functions and apply this basis to the state variables after scaling them
to be between 0 and 1. Each model also implicitly contains an intercept.
We begin with the following simple generative model. Let the two-dimensional state
vector be Sti = (S
t
i,1, S
t
i,2)
⊺, i = 1, . . . , n, t = 1, . . . , T . We initiate the state variables
as independent standard normal random variables and let them evolve according to
Sti,1 = (3/4)(2A
t−1
i − 1)St−1i,1 + (1/4)St−1i,1 St−1i,2 + ǫt1 and Sti,2 = (3/4)(1 − 2At−1i )St−1i,2 +
(1/4)St−1i,1 S
t−1
i,2 + ǫ
t
2, where A
t
i takes values in {0, 1} and ǫt1 and ǫt2 are independent
N(0, 1/4) random variables. Define the utility function by U ti = u(S
t+1
i , A
t
i,S
t
i) =
2St+1i,1 + S
t+1
i,2 − (1/4)(2Ati− 1). At each time t, we must make a decision to treat or not
with the goal of maximizing the components of S while treating as few times as possible.
Treatment has a positive effect on S1 and a negative effect on S2. We generate A
t
i from
a Bernoulli distribution with mean 1/2. In estimation, we assume that the generating
model for treatment is known, as would be the case in a micro-randomized trial.
We generate samples of n patients with T time points per patient from the given
generative model after an initial burn-in period of 50 time points. The burn-in period
ensures that our simulated data is sampled from an approximately stationary distribu-
tion. We estimate policies using V-learning with three different types of basis functions
and GGQ. After estimating optimal policies, we simulate 100 patients following each
estimated policy for 100 time points and take the mean utility under each policy as
an estimate of the value of that policy. Estimated values are found in Table 1 with
Monte Carlo standard errors along with observed value. Recall that larger values are
better. The policies estimated using V-learning produce better outcomes than the ob-
servational policy and the policy estimated using GGQ. V-learning produces the best
outcomes using Gaussian basis functions.
Next, we simulate cohorts of patients with type 1 diabetes to mimic the mHealth
study of Maahs et al. (2012). Maahs et al. (2012) followed a small sample of youths with
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n T Linear VL Polynomial VL Gaussian VL GGQ Observed
25 24 0.118 (0.0892) 0.091 (0.0825) 0.110 (0.0979) 0.014 (0.0311) −0.005
36 0.108 (0.0914) 0.115 (0.0911) 0.112 (0.0919) 0.029 (0.0280) −0.004
48 0.106 (0.0705) 0.071 (0.0974) 0.103 (0.0757) 0.031 (0.0350) 0.000
50 24 0.124 (0.0813) 0.109 (0.1045) 0.118 (0.0879) 0.016 (0.0355) −0.005
36 0.126 (0.0818) 0.134 (0.0878) 0.136 (0.0704) 0.027 (0.0276) 0.003
48 0.101 (0.0732) 0.109 (0.0767) 0.115 (0.0763) 0.020 (0.0245) 0.000
100 24 0.117 (0.0895) 0.135 (0.0973) 0.140 (0.0866) 0.019 (0.0257) 0.011
36 0.113 (0.0853) 0.105 (0.1033) 0.139 (0.0828) 0.021 (0.0312) 0.012
48 0.111 (0.0762) 0.143 (0.0853) 0.114 (0.0699) 0.031 (0.0306) −0.001
Table 1: Monte carlo value estimates for offline simulations with γ = 0.9.
type 1 diabetes and recorded data at a fine granularity using mobile devices. Blood
glucose levels were tracked in real time using continuous glucose monitoring, physical
activity was measured continuously using accelerometers, and insulin injections were
logged by an insulin pump. Dietary data were recorded by 24-hour recall over phone
interviews.
In our simulation study, we divide each day of follow-up into 60 minute intervals.
Thus, for one day of follow-up, we observe T = 24 time points per simulated patient and
a treatment decision is made every hour. Our hypothetical mHealth study is designed
to estimate an optimal dynamic treatment regime for the timing of insulin injections
based on patient blood glucose, physical activity, and dietary intake with the goal of
controlling future blood glucose as close as possible to the optimal range. To this end,
we define the utility at time t as a weighted sum of hypo- and hyperglycemic episodes
in the 60 minutes preceding and following time t. Weights are −3 when glucose ≤ 70
(hypoglycemic), −2 when glucose > 150 (hyperglycemic), −1 when 70 < glucose ≤ 80
or 120 < glucose ≤ 150 (borderline hypo- and hyperglycemic), and 0 when 80 <
glucose ≤ 120 (normal glycemia). Utility at each time point ranges from −6 to 0 with
larger utilities (closer to 0) being more preferable. For example, a patient who presents
with an average blood glucose of 155 mg/dL over time interval t− 1, takes an action to
correct their hyperglycemia, and presents with an average blood glucose of 145 mg/dL
over time interval t would receive a utility of U t = −3. Weights were chosen to reflect
the relative clinical consequences of high and low blood glucose. For example, acute
hypoglycemia, characterized by blood glucose levels below 70 mg/dL, is an emergency
that can result in coma or death.
Simulated data are generated as follows. At each time point, patients are randomly
chosen to receive an insulin injection with probability 0.3, consume food with probability
0.2, partake in mild physical activity with probability 0.4, and partake in moderate
physical activity with probability 0.2. Grams of food intake and counts of physical
activity are generated from normal distributions with parameters estimated from the
data of Maahs et al. (2012). Initial blood glucose level for each patient is drawn from
a normal distribution with mean 100 and standard deviation 25. Define the covariates
for patient i collected at time t by (Glti,Di
t
i,Ex
t
i)
⊺, where Glti is average blood glucose
level, Diti is total dietary intake, and Ex
t
i is total counts of physical activity as would
12
be measured by an accelerometer. Glucose levels evolve according to
Glt = µ(1−α1)+α1Glt−1+α2Dit−1+α3Dit−2+α4Ext−1+α5Ext−2+α6Int−1+α7Int−2+e,
(8)
where Int is an indicator of an insulin injection received at time t and e ∼ N(0, σ2).
We use the parameter vector α = (α1, . . . , α7)
⊺ = (0.9, 0.1, 0.1,−0.01,−0.01,−2,−4)⊺,
µ = 100, and σ = 5.5 based on a linear model fit to the data of Maahs et al. (2012). The
known lag-time in the effect of insulin is reflected by α6 = −2 and α7 = −4. Selecting
α1 < 1 ensures the existence of a stationary distribution.
We define the state vector for patient i at time t to contain average blood glucose,
total dietary intake, and total physical activity measured over previous time intervals;
we include blood glucose and physical activity for the previous two time intervals and
dietary intake for the previous four time intervals. Let n denote number of patients
and T denote number of time points per patient. Our choices for n and T are based
on what is feasible for an mHealth outpatient study (dietary data was collected on
two days by Maahs et al., 2012). For each replication, the optimal treatment regime is
estimated with V-learning using three different types of basis functions and GGQ. The
generative model for insulin treatment is not assumed to be known and we estimate
it using logistic regression. We record mean outcomes in an independent sample of
100 patients followed for 100 time points with treatments generated according to each
estimated optimal regime. Simulation results (estimated values under each regime and
Monte Carlo standard errors along with observed values) are found in Table 2. Again, V-
n T Linear VL Polynomial VL Gaussian VL GGQ Observed
25 24 −2.716 (1.2015) −2.335 (0.9818) −2.018 (1.2011) −3.870 (0.9225) −2.316
36 −2.700 (1.2395) −2.077 (1.0481) −1.760 (0.8468) −3.644 (0.8745) −2.261
48 −2.496 (1.1986) −2.236 (1.1978) −1.751 (0.9887) −2.405 (1.1025) −2.365
50 24 −2.545 (1.1865) −2.069 (1.0395) −1.605 (0.8064) −3.368 (1.0186) −2.263
36 −2.644 (1.1719) −2.004 (0.9074) −1.778 (0.8496) −3.099 (0.9722) −2.336
48 −2.469 (1.1635) −2.073 (0.9870) −2.102 (1.2078) −2.528 (0.9571) −2.308
100 24 −2.350 (1.1171) −2.128 (1.0520) −1.612 (0.7203) −3.272 (0.8636) −2.299
36 −2.547 (1.1852) −2.116 (0.8518) −1.672 (0.8643) −3.232 (0.7951) −2.321
48 −2.401 (1.0643) −2.204 (1.0400) −1.494 (0.5413) −2.820 (0.8442) −2.351
Table 2: Monte carlo value estimates for simulated T1D cohorts with γ = 0.9.
learning with Gaussian basis functions performs the best out of all methods, generally
producing large values and small standard errors. V-learning with the linear model
underperforms and GGQ underperforms considerably.
5.3 Online simulations
In practice, it may be useful for patients to follow a dynamic treatment regime that
is updated as new data are collected. Here we consider a hypothetical study wherein
n patients are followed for an initial period of T ′ time points, an optimal policy is
estimated, and patients are followed for an additional T − T ′ time points with the
estimated optimal policy being continuously updated. At each time point, t ≥ T ′,
actions are taken according to the most recently estimated policy. Recall that V-learning
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produces a randomized decision rule from which to sample actions at each time point.
When selecting an action based on a GGQ policy, we incorporate an ǫ-greedy strategy
by selecting the action recommended by the estimated policy with probability 1 − ǫ
and otherwise randomly selecting one of the other actions. At the tth estimation, we
use ǫ = 0.5t, allowing ǫ to decrease over time to reflect increasing confidence in the
estimated policy. A burn-in period of 50 time points is discarded to ensure that we
are sampling from a stationary distribution. We estimate the first policy after 12 time
points and a new policy is estimated every 6 time points thereafter. After T time points,
we estimate the value as the average utility over all patients and all time points after
the initial period.
Table 3 contains mean outcomes under policies estimated online using data gener-
ated according to the simple two covariate generative model introduced at the beginning
of Section 5.2. There is some variability across n and T regarding which type of basis
n T Linear VL Polynomial VL Gaussian VL GGQ
25 24 0.0053 0.0149 −0.0100 −0.0081
36 0.0525 0.0665 0.0310 0.0160
48 0.0649 0.0722 0.0416 0.0493
50 24 0.0164 0.0117 0.0037 0.0058
36 0.0926 0.0791 0.0666 0.0227
48 0.1014 0.0894 0.0512 0.0434
100 24 0.0036 −0.0157 0.0200 0.0239
36 0.0766 0.0626 0.0907 0.0540
48 0.0728 0.0781 0.0608 0.0818
Table 3: Value estimates for online simulations with γ = 0.9.
function is best, but V-learning with a polynomial basis generally produces the best
outcomes. GGQ performs well in large samples but underperforms somewhat otherwise.
Next, we study the performance of online V-learning in simulated mHealth studies of
type 1 diabetes by following the generative model described in (8). Mean outcomes are
found in Table 4. Gaussian V-learning performs the best out of all methods, with GGQ
n T Linear VL Polynomial VL Gaussian VL GGQ
25 24 −2.3887 −1.9713 −1.8860 −3.2027
36 −2.3784 −2.1535 −1.7857 −3.5127
48 −2.2190 −2.0679 −1.6999 −3.2280
50 24 −2.3405 −2.2313 −1.7761 −2.8976
36 −2.2829 −2.0922 −1.6016 −3.1589
48 −2.1587 −1.9669 −1.5948 −2.8729
100 24 −2.3229 −2.2295 −1.9138 −3.0865
36 −2.2927 −2.1608 −1.9030 −3.3483
48 −2.2096 −2.0454 −1.8252 −2.9428
Table 4: Value estimates for online estimation of simulated T1D cohorts with γ = 0.9
consistently underperforming. Across all variants of V-learning, outcomes improve with
increased follow-up time.
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Finally, we consider online simulations using individualized policies as outlined at the
end of Section 3. Consider the simple two covariate generative model introduced above
but let state variables evolve according to Sti,1 = µi(2A
t−1
i −1)St−1i,1 +(1/4)St−1i,1 St−1i,2 + ǫt1
and Sti,2 = µi(1 − 2At−1i )St−1i,2 + (1/4)St−1i,1 St−1i,2 + ǫt2 where µi is a subject-specific term
drawn uniformly between 0.4 and 0.9. Including µi ensures that the optimal policy
differs across patients. Table 5 contains mean outcomes for online simulation where
a universal policy is estimated using data from all patients and where individualized
policies are estimated using only a single patient’s data. Because data is generated in a
n T Universal policy Patient-specific policy
25 24 0.0282 0.1813
36 0.1025 0.1700
48 0.0977 0.1944
50 24 0.0164 0.2771
36 0.0768 0.2617
48 0.0752 0.3038
100 24 0.0160 0.4230
36 0.0960 0.2970
48 0.1140 0.3197
Table 5: Value estimates for online V-learning simulations with univeral and patient-
specific policies when γ = 0.9.
such a way that the optimal policy varies across patients, individualized policies achieve
better outcomes than universal policies.
6 Case study: Type 1 diabetes
Machine learning is currently under consideration in type 1 diabetes through studies to
build and test a “closed loop” system that joins continuous blood glucose monitoring and
subcutaneous insulin infusion through an underlying algorithm. Known as the artificial
pancreas, this technology has been shown to be safe in preliminary studies and is making
headway from small hospital-based safety studies to large-scale outpatient effectiveness
studies (Ly et al., 2014, 2015). Despite the success of the artificial pancreas, the rate
of uptake may be limited and widespread use may not occur for many years (Kowalski,
2015). The proposed method may be useful for implementing mHealth interventions
for use alongside the artificial pancreas or before it is widely available.
Studies have shown that data on food intake and physical activity to inform optimal
decision making can be collected in an inpatient setting (see, e.g., Cobry et al., 2010;
Wolever and Mullan, 2011). However, Maahs et al. (2012) demonstrated that rich data
on the effect of food intake and physical activity can be collected in an outpatient setting
using mobile technology. Here, we apply the proposed methodology to the observational
data collected by Maahs et al. (2012).
The full data consist of N = 31 patients with type 1 diabetes, aged 12–18. Glucose
levels were monitored using continuous glucose monitoring and physical activity tracked
using accelerometers for five days. Dietary data were self-reported by the patient in
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telephone-based interviews for two days. Patients were treated using either an insulin
pump or multiple daily insulin injections. We use data on a subset of n = 14 patients
treated with an insulin pump for whom full follow-up is available on days when dietary
information was recorded. This represents 28 patient-days of data, with which we use
V-learning to estimate an optimal treatment policy.
The setup closely follows the simulation experiments in Section 5.2. Patient state
at each time, t, is taken to be average glucose level and total counts of physical activity
over the two previous 60 minute intervals and total food intake in grams over the
four previous 60 minute intervals. The goal is to learn a policy to determine when to
administer insulin injections based on prior blood glucose, dietary intake, and physical
activity. The utility at time t is a weighted sum of glycemic events over the 60 minutes
preceding and following time t with weights defined in Section 5.2. A treatment regime
with large value will minimize the number of hypo- and hyperglycemic episodes weighted
to reflect the clinical importance of each. We note that because V (π, s; θpi) is linear in
θpi, we can evaluate V̂n,R̂(π) with only the mean of Φ(S) under R. These were estimated
from the data. Because we cannot simulate data following a given policy to estimate its
value, we report the parametric value estimate V̂n,R̂ (π̂n). Interpreting the parametric
value estimate is difficult because of the effect the discount factor has on estimated
value. We cannot compare parametric value estimates to mean outcomes observed in
the data. Instead, we use En
∑
t≥0 γ
tU t as an estimate of value under the observational
policy.
We estimate optimal treatment strategies for two different action spaces. In the first,
the only decision made at each time is whether or not to administer an insulin injection,
i.e., the action space contains a single binary action. In the second, the action space
contains all possible combinations of insulin injection, physical activity, and food intake.
This corresponds to a hypothetical mHealth intervention where insulin injections are
administered via an insulin pump and suggestions for physical activity and food intake
are administered via a mobile app.
Table 6 contains parametric value estimates for policies estimated using V-learning
for the two action spaces outlined above with different basis functions and discount
factors. These results indicate that improvements in glycemic control can come from
Action space Basis γ = 0.7 γ = 0.8 γ = 0.9
Binary Linear −6.20 −9.35 −15.99
Polynomial −3.91 −9.03 −17.50
Gaussian −3.44 −13.09 −25.52
Multiple Linear −6.47 −9.92 −0.49
Polynomial −2.44 −6.80 −14.48
Gaussian −8.45 −3.58 −21.18
Observational policy −6.77 −11.28 −21.79
Table 6: Parametric value estimates for V-learning applied to type 1 diabetes data.
personalized and dynamic treatment strategies that account for food intake and physi-
cal activity. Improvement results from a dynamic insulin regimen (binary action space)
and in most cases, further improvement results from a comprehensive mHealth inter-
vention including suggestions for diet and exercise delivered via mobile app in addition
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to insulin therapy (multiple action space). When considering multiple actions, the pol-
icy estimated using a polynomial basis and γ = 0.7 achieves a 64% increase in value
and the policy estimated using a Gaussian basis and γ = 0.8 achieves a 68% increase
in value over the observational policy.
Finally, we use an example hyperglycemic patient to illustrate how an estimated
policy would be applied in practice. One patient in the data presented at a specific time
with an average blood glucose of 229 mg/dL over the previous hour and an average
blood glucose of 283 mg/dL over the hour before that. The policy estimated with
γ = 0.7 and a polynomial basis recommends each action according to the probabilities
in Table 7. Because this patient presented with blood glucose levels that are higher
Action Probability
No action < 0.0001
Physical activity < 0.0001
Food intake < 0.0001
Food and activity < 0.0001
Insulin 0.7856
Insulin and activity 0.2143
Insulin and food 0.0002
Insulin, food, and activity < 0.0001
Table 7: Probabilities for each action as recommended by estimated policy for one
example patient.
than the optimal range, the policy recommends actions that would lower the patient’s
blood glucose levels, assigning a probability of 0.79 to insulin and a probability of 0.21
to insulin combined with activity.
7 Conclusion
The emergence of mHealth has provided great potential for the estimation and imple-
mentation of dynamic treatment regimes. Mobile technology can be used both in the
collection of rich longitudinal data to inform decision making and the delivery of deeply
tailored interventions. The proposed method, V-learning, addresses a number of chal-
lenges associated with estimating dynamic treatment regimes in mHealth applications.
V-learning directly estimates a policy which maximizes the value over a class of poli-
cies and requires minimal assumptions on the data-generating process. Furthermore,
V-learning permits estimation of a randomized decision rule which can be used in place
of existing strategies (e.g., ǫ-greedy) to encourage exploration in online estimation. A
randomized decision rule can also provide patients with multiple treatment options.
Estimation of an optimal policy for different populations can be handled through the
use of different reference distributions.
V-learning and mobile technology have the potential to improve patient outcomes
in a variety of clinical areas. We have demonstrated, for example, that the proposed
method can be used to estimate treatment regimes to reduce the number of hypo-
and hyperglycemic episodes in patients with type 1 diabetes. The proposed method
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could also be useful for other mHealth applications as well as applications outside of
mHealth. For example, V-learning could be used to estimate dynamic treatment regimes
for chronic illnesses using electronic health records data. Future research in this area
may include increasing flexibility through use of a semiparametric model for the state-
value function. Alternatively, nonlinear models for the state-value function may be
informed by underlying theory or mathematical models of the system of interest. Data-
driven selection of tuning parameters for the proposed method may help to improve
performance. Finally, accounting for patient availability and feasibility of a sequence
of treatments can be done by setting constraints on the class of policies. This will
ensure that the resulting mHealth intervention is able to be implemented and that the
recommended decisions are consistent with domain knowledge.
Appendix
Proof of Lemma 2.1. Let π be an arbitrary policy and γ ∈ (0, 1) a fixed constant.
Suppose we observe a state St = st at time t and let at−1 = (a1, . . . , at−1) be the
sequence of actions resulting in St = st, i.e., S∗t(at−1) = st. Let ak+1 = (at, . . . , at+k) ∈
Ak+1 be a potential sequence of actions taken from time t to time t+ k. We have that
V (π, st) =
∑
k≥0
γkE
{
U∗(t+k)(π)
∣∣∣∣St = st}
=
∑
k≥0
γkE
 ∑
at+k∈At+k
U∗(t+k)(at+k)
t+k∏
v=t
1
[
ξvpi
{
S
∗v(av−1)
}
= av
] ∣∣∣∣St = st

=
∑
k≥0
γk
∑
ak+1∈Ak+1
U∗(t+k)(at−1, ak+1)
{
t+k∏
v=t
E
(
1
[
ξvpi
{
S
∗v(av−1)
}
= av
] ∣∣∣∣St = st)
}
=
∑
k≥0
γk
∑
ak+1∈Ak+1
U∗(t+k)(at−1, ak+1)
t+k∏
v=t
π
{
av;S∗v(av−1)
} t+k∏
v=t
µv {av;S∗v(av−1)}
µv {av;S∗v(av−1)}
=
∑
k≥0
γkE
[
U t+k
{
k∏
v=0
π(at+v; st+v)
µt+v(at+v; st+v)
}∣∣∣∣St = st
]
,
where we let π(at; st) = 0 for all at and st whenever t > T ∗(π). The last equality uses
the consistency and strong ignorability assumptions.
Proof of Theorem 4.2. Proof of part 1: We first note that θpi0 must solve
0 = E
(
π(At;St)
µt(At;St)
[
U t +
{
γΦ(St+1)− Φ(St)}⊺ θpi]Φ(St)) ,
or
E
[
π(At;St)
µt(At;St)
Φ(St)
{
Φ(St)− γΦ(St+1)}⊺] θpi = E{ π(At;St)
µt(At;St)
U tΦ(St)
}
,
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which is equivalent to w1(π)θ
pi = w2(π) where w2(π) = E
{
π(At;St)µt(At;St)−1U tΦ(St)
}
.
We have that∥∥∥∥E{ π(At;St)µt(At;St)U tΦ(St)
}∥∥∥∥ ≤ c−10 (E|U t|2)1/2 (E‖Φ(St)‖2)1/2 <∞,
by assumption 3, part 1 of assumption 4 and the Cauchy–Schwarz inequality. Let c ∈ Rq
be arbitrary and note that
E
{
π(At;St)
µt(At;St)
c⊺Φ(St)Φ(St+1)⊺c
}
≤
[
E
{
π(At;St)
µt(At;St)
c⊺Φ(St)⊗2c
}
· E
{
π(At;St)
µt(At;St)
c⊺Φ(St+1)⊗2c
}]1/2
,
by the Cauchy–Schwarz inequality, where u⊗2 = uu⊺. This implies that
c⊺w1(π)c ≥ E
{
π(At;St)
µt(At;St)
c⊺Φ(St)⊗2c
}
−E
{
π(At;St)
µt(At;St)
c⊺Φ(St)⊗2c
}1/2
E
{
γ2
π(At;St)
µt(At;St)
c⊺Φ(St+1)⊗2c
}1/2
= A− A1/2B1/2
= A1/2(A1/2 − B1/2)
=
A1/2(A− B)
A1/2 +B1/2
,
where we simplify notation by defining A = E
{
π(At;St)µt(At;St)−1c⊺Φ(St)⊗2c
}
and
B = E
{
γ2π(At;St)µt(At;St)−1c⊺Φ(St+1)⊗2c
}
. We have that
A1/2 +B1/2 ≤ c−1/20 ‖c‖
{
E‖Φ(St)‖2}1/2 + c−1/20 ‖c‖{E‖Φ(St+1)‖2}1/2
= 2c
−1/2
0 ‖c‖
{
E‖Φ(St)‖2}1/2
< ∞,
by the Cauchy–Schwarz inequality, the fact that E‖Φ(St)‖2 = E‖Φ(St+1)‖2 by time-
homogeneity, and part 1 of assumption 4. Also, A ≥ A − B and A − B ≥ c1‖c‖2 by
assumption 5. Thus,
A−A1/2B1/2 ≥ c
3/2
1 ‖c‖3
2c
−1/2
0 ‖c‖
{
E‖Φ(St)‖2}1/2
=
c
1/2
0 c
3/2
1 ‖c‖2
2
{
E‖Φ(St)‖2}1/2 ,
which finally implies that w1(π) is invertible and thus θ
pi
0 = w1(π)
−1w2(π) is well-
defined uniformly over π ∈ Π. Using the fact that c⊺w1(π)c ≥ k0‖c‖2 for a constant
k0 > 0, we can show that ‖w1(π)−1‖ ≤ k−11 for some constant k1 > 0, where ‖ · ‖ is
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the usual matrix norm when applied to a matrix. Therefore, ‖θpi0‖ ≤ k−11 ‖w2(π)‖ ≤
c−10 k
−1
1 {E(U t)2}1/2
{
E‖Φ(St)‖2}1/2 < ∞. Finally, it follows from assumptions 5 and 7
that sup‖β1−β2‖≤δ ‖θpiβ1 − θpiβ2‖ → 0 as δ ↓ 0.
Proof of part 2: Define
G = {Φ(st)Φ(st)⊺/µt(at; st), γΦ(st)Φ(st+1)⊺/µt(at; st), utΦ(st)/µt(at; st)} .
Let G be an envelope for G, for example G(st+1, at, st) = maxg∈G g(st+1, at, st). By
part 1 of assumption 4, EG3ρ < ∞. Part 4 of Lemma 7.1 below gives us that G is
Donsker. Since Π satisfies J[] {∞,Π, L3ρ(P )} <∞, we have that
F1 =
{
π(at; st)
µt(at; st)
Φ(st)
{
Φ(st)− γΦ(st+1)}⊺ : π ∈ Π}
satisfies J[] {∞,F1, L3ρ(P )} < ∞ by parts 1 and 2 of Lemma 7.1 below. Moreover,
F (at, st) = ‖Φ(st)‖·‖Φ(st)−γΦ(st+1)‖/µt(at; s⊺) is an envelope for F1 with EF 3ρ <∞
by assumption 3 and part 1 of assumption 4. Thus, F1 is Donsker. Let
F2 =
{
π(at; st)
µt(at; st)
utΦ(st) : π ∈ Π
}
.
Similar arguments yield that F2 is Donsker.
Now, let Â(π) = {Enf1pi : f1pi ∈ F1} and B̂(π) = {Enf2pi : f2pi ∈ F2}. Let Â′(π) =
Â(π) + λnÂ(π)
−1. We have that θ̂pin = Â
′(π)−1B̂(π). Thus,
√
n
(
θ̂pin − θpi0
)
=
√
n
{
Â′(π)−1B̂(π)− Â′(π)−1Â′(π)θpi0
}
+ oP (1)
= Â′(π)−1
√
n
{
B̂(π)− Â′(π)θpi0
}
+ oP (1)
= Â′(π)−1
√
n
{
B̂(π)− Â(π)θpi0
}
+ Â′(π)−1
√
n
{
Â(π)− Â′(π)
}
θpi0 + oP (1)
= Â′(π)−1
√
n
{
B̂(π)− Â(π)θpi0
}
+ oP (1)
where oP (1) doesn’t depend on π, because Â
′(π)−1
P−→ w1(π)−1 < ∞ uniformly over
π ∈ Π by assumption 3 and part 1 of assumption 4, suppi∈Π ‖θpi0‖ <∞ by part 1 of this
theorem, and
√
n
{
Â(π)− Â′(π)
}
=
√
nλnÂ(π)
−1 = oP (1) because λn = oP (n
−1/2).
Using arguments similar to those in the previous paragraph, one can show that F3 =
{f2pi − f1piθ : f1pi ∈ F1, f2pi ∈ F2, π ∈ Π, θ ∈ B∗} is Donsker, where B∗ is any finite col-
lection of elements of Rq. By part 1 of this theorem, there exists a bounded, closed set
B0 such that θ
pi
0 ∈ B0 for all π ∈ Π. Let Gn(π, θ) =
√
n(En −E)(f2pi − f1piθ). Note that
sup
pi∈Π
‖Gn(π, θ1)−Gn(π, θ2)‖ ≤ sup
pi∈Π
‖√n(En − E)f1pi‖ · ‖θ1 − θ2‖
≤ R∗‖θ1 − θ2‖,
where R∗ = OP (1) by the Donsker property of F1 and R∗ doesn’t depend on π. Thus,
Gn(π, θ) is stochastically equicontinuous on B0. Combined with the Donsker property
of F3 for arbitrary B∗, we have that the class F4 = {f2pi−f1piθ : f1pi ∈ F1, f2pi ∈ F2, π ∈
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Π, θ ∈ B0} is Donsker. Using Slutsky’s Theorem, Theorem 11.24 of Kosorok (2008), the
fact that F1 is Glivenko–Cantelli, and the fact that θpi0 = (Ef1pi)−1Ef2pi, we have that√
n
(
θ̂pin − θpi0
)
= Â′(π)−1Gn(π, θ
pi
0 )  w1(π)
−1G0(π) in ℓ
∞(Π), where G0(π) is a mean
zero Gaussian process indexed by Π with covariance E {G0(π1)G0(π2)} = w0(π1, π2).
Proof of part 3: We have that
√
n
{
V̂n,R̂(π)− VR(π)
}
=
√
nEnΦ(S
t)
(
θ̂pin − θpi0
)
 ν⊺w1(π)
−1
G0(π)
in ℓ∞(Π) by Slutsky’s Theorem.
Proof of Theorem 4.3. Proof of part 1: Following part 3 of Theorem 4.2, we have that
supβ∈B
∣∣∣V̂n,R̂(πβ)− VR(πβ)∣∣∣ P−→ 0. Combining this with the unique and well separated
maximum condition (assumption 6), continuity of VR(πβ) in β, and Theorem 2.12 of
Kosorok (2008) yields the result in part 1. Part 2 follows from parts 2 and 3 of Theo-
rem 4.2. The proof of part 3 follows standard arguments.
Lemma 7.1. Let F and G be function classes with respective envelopes F and G. Let
‖F‖u = (E|F |u)1/u. For any 1 ≤ r, s1, s2 ≤ ∞ with s−11 + s−12 = 1,
1. J[]{∞,F·G, Lr(P )} ≤ 2 (‖F‖rs1 + ‖G‖rs2)
[
J[]{∞,F , Lrs1(P )}+ J[]{∞,G, Lrs2(P )}
]
.
2. J[]{∞,F + G, Lr(P )} ≤ 2
[
J[]{∞,F , Lr(P )}+ J[]{∞,G, Lr(P )}
]
.
3. For any 0 ≤ r ≤ ∞, J[]{∞,F∪G, Lr(P )} ≤
√
log 2(‖F‖r+‖G‖r)+J[]{∞,F , Lr(P )}+
J[]{∞,G, Lr(P )}.
4. If G is a finite class, J[]{∞,G, Lr(P )} ≤ 2‖G‖r
√
log |G|, where |G| denotes the
cardinality of G.
Proof of Lemma 7.1. Proof of part 1: Let 1 ≤ r, s1, s2 ≤ ∞ with s−11 + s−12 = 1 and
let (ℓF , uF ) and (ℓG, uG) be Lrs1(P ) and Lrs2(P ) ǫ-brackets, respectively. Choose ℓF ≤
f1, f2 ≤ uF and ℓG ≤ g1, g2 ≤ uG and consider the bracket for any f2g2 defined by
f1g1 ± (F |uG − ℓG|+G|uF − ℓF |). Note that
f1g1+F |uG−ℓG|+G|uF−ℓF |−f2g2 ≥ F |uG−ℓG|+G|uF−ℓF |−F |g1−g2|−G|f1−f2| ≥ 0,
because f2g2 − f1g1 = f2g2 + f2g1 − f2g1 − f1g1 ≤ F |g1 − g2| + G|f1 − f2|. Similarly,
f2g2 + F |uG − ℓG| + G|uF − ℓF | − f1g1 ≥ 0. Thus, these brackets hold all f2g2 for
f2 ∈ (ℓF , uF ) and g2 ∈ (ℓG, uG). Now, ‖F |uG− ℓG|+G|uF − ℓF |‖r ≤ ‖F‖rs1ǫ+ ‖G‖rs2ǫ
by Minkowski’s inequality and Ho¨lder’s inequality and it follows that
N[] {2ǫ(‖F‖rs1 + ‖G‖rs2),F · G, Lr(P )} ≤ N[] {ǫ,F , Lrs1(P )}N[] {ǫ,G, Lrs2(P )} .
Next we note that
N[] {ǫ,F · G, Lr(P )} ≤ N[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,F , Lrs1(P )
}
N[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,G, Lrs2(P )
}
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and thus
J[] {∞,F · G, Lr(P )} ≤
∫ 2‖F‖rs1‖G‖rs2
0
√
logN[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,F , Lrs1(P )
}
dǫ
+
∫ 2‖F‖rs1‖G‖rs2
0
√
logN[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,G, Lrs2(P )
}
dǫ
≤ 2 (‖F‖rs1 + ‖G‖rs2)
[
J[]{∞,F , Lrs1(P )}+ J[]{∞,G, Lrs2(P )}
]
.
The proof of part 2 follows from Lemma 9.25 part (i) of Kosorok (2008) after a
change of variables. Proof of part 3: First note that
N[] {ǫ,F ∪ G, Lr(P )} ≤ N[] {ǫ,F , Lr(P )}+N[] {ǫ,G, Lr(P )} ,
whence it follows that
J[] {∞,F ∪ G, Lr(P )} =
∫ 2(‖F‖r+‖G‖r)
0
√
logN[] {ǫ,F ∪ G, Lr(P )}dǫ
≤
∫ 2(‖F‖r+‖G‖r)
0
√
log
[
N[] {ǫ,F , Lr(P )}+N[] {ǫ,G, Lr(P )}
]
dǫ
≤
∫ 2(‖F‖r+‖G‖r)
0
√
log 2 + logN[] {ǫ,F , Lr(P )}+ logN[] {ǫ,G, Lr(P )}dǫ
≤
∫ 2(‖F‖r+‖G‖r)
0
√
log 2dǫ+ J[] {∞,F , Lr(P )}+ J[] {∞,G, Lr(P )} ,
where the second inequality uses the fact that a+ b ≤ 2ab for all a, b ≥ 1.
Proof of part 4: If G is finite, then N[] {ǫ,G, Lr(P )} ≤ |G|. Thus,
J[] {∞,G, Lr(P )} =
∫ 2‖G‖r
0
√
logN[] {ǫ,G, Lr(P )}dǫ
≤
∫ 2‖G‖r
0
√
log |G|dǫ,
which completes the proof.
Lemma 7.2. Define the class of functions
Π =
{
πβ˜(a; s) =
aJ +
∑J−1
j=1 ajexp(s
⊺
jβj)
1 +
∑J−1
j=1 exp(s
⊺
jβj)
: β˜ = (β⊺1 , . . . , β
⊺
J−1)
⊺, β˜ ∈ B ⊂ Rp(J−1)
}
for a compact set B and 2 ≤ J < ∞ where a = (a1, . . . , aJ)⊺. Then, there exists a
b0 <∞ such that for any 1 ≤ r ≤ ∞, J[]{∞,Π, Lr(P )} ≤ b0‖S‖r
√
p(J − 1)π, which is
finite whenever ‖S‖r < ∞. Furthermore, sup‖β˜1−β˜2‖≤δ E‖πβ˜1(A;S) − πβ˜2(A;S)‖ → 0
as δ ↓ 0.
Proof of Lemma 7.2. For β˜1, β˜2 ∈ B, define d(β˜1, β˜2) = max1≤j≤J−1‖β˜1j − β˜2j‖ and
b0 = supβ˜1,β˜2∈B ‖β˜1 − β˜2‖ < 0 because B is compact. By the mean value theorem, for
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any β˜1, β˜2 ∈ B, there exists a point β˜∗ on the line segment between β˜1 and β˜2 such that
πβ˜1(a; s)−πβ˜2(a; s) =
1
1 +
∑J−1
j=1 exp(s
⊺β˜∗j)
[
J−1∑
j=1
{
aj − πβ˜∗(a; s)
}
exp(s⊺β˜∗j)s
⊺(β˜1j − β˜2j)
]
,
which implies that
|πβ˜1(a; s)− πβ˜2(a; s)| ≤ ‖s‖d(β˜1, β˜2). (9)
It follows from equation (9) that assumption 7 holds for this particular class of poli-
cies. Now, N[] {2ǫ‖S‖r,Π, Lr(P )} ≤ N(ǫ,B, d) by Theorem 9.23 of Kosorok (2008).
Furthermore, N(ǫ,B, d) ≤ max{(b0/ǫ)p(J−1), 1}, and thus
J[] {ǫ,Π, Lr(P )} ≤ 2‖S‖r
∫ b0
0
√
p(J − 1) {log b0 + log(1/ǫ)}dǫ
≤ 2‖S‖rb0
√
p(J − 1)
∫ 1
0
√
log(1/ǫ)dǫ
= 2‖S‖rb0
√
p(J − 1)
∫ ∞
0
u1/2exp(−u)du
= ‖S‖rb0
√
p(J − 1)π,
which proves the result.
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